Related Experiment Video
Updated: Aug 24, 2025
07:14
Minimally Invasive Cisterna Magna Injection Model for Leptomeningeal Metastasis Studies in Mice
Published on: May 23, 2025
423
Primary CNS lymphoma: update on molecular pathogenesis and therapy
Shirley S Mo1, Joseph Cleveland1, James L Rubenstein1,2,3
1Department of Medicine, University of California, San Francisco, CA, USA.
Leukemia & Lymphoma
|October 26, 2022
Summary
Primary central nervous system lymphoma (PCNSL) is a rare brain tumor. Advances in genomic understanding and novel therapies like CAR-T offer improved treatment strategies for PCNSL.
Area of Science:
- Neuro-oncology
- Hematology
- Genomics
Background:
- Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin lymphoma.
- PCNSL presents unique diagnostic and management challenges as a brain tumor.
Approach:
- Review of molecular and genomic pathogenesis using next-generation sequencing.
- Focus on emerging therapeutic technologies and biological agents.
Key Points:
- Novel therapies include monoclonal antibodies, IMiDs, BTK inhibitors, PD-1 inhibitors, and CAR-T therapy.
- Integration of these therapies aims to enhance treatment efficacy.
- Strategies focus on suppressing NF-κB activation and anti-tumor immunity.
Conclusions:
- New approaches may improve induction and consolidation strategies for PCNSL.
- Minimizing toxic effects of genotoxic treatments is a key objective.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K